Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3

Journal of Immunology

Volumn 190, Issue 7, 2013, Pages 3533-3540

  Lewis, Nuruddeen D ^a   Haxhinasto, Sokol A ^a   Anderson, Shawn M ^a   Stefanopoulos, Dimitria E ^a   Fogal, Steven E ^a   Adusumalli, Prathima ^a   Desai, Sudha N ^a   Patnaude, Lori A ^a   Lukas, Susan M ^a   Ryan, Kelli R ^a   Slavin, Anthony J ^a   Brown, Maryanne L ^a   Modis, Louise K ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAF 312; CD40 ANTIGEN; FINGOLIMOD; IMMUNOMODULATING AGENT; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; IMMUNOMODULATION; IN VIVO STUDY; LEUKOCYTE ACTIVATION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPLEEN;

ANIMALS; BONE MARROW; CELL MOVEMENT; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; KILLER CELLS, NATURAL; LEUKOCYTE COUNT; MICE; MONOCYTES; NEUTROPHILS; PROPYLENE GLYCOLS; RATS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; SPLEEN;

EID: 84875465529     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201810     Document Type: Article

References (39)

1. Cyster, J. G., and S. R. Schwab. 2012. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu. Rev. Immunol. 30: 69-94.
2. Rivera, J., R. L. Proia, and A. Olivera. 2008. The alliance of sphingosine-1- phosphate and its receptors in immunity. Nat. Rev. Immunol. 8: 753-763.
3. Brinkmann, V., A. Billich, T. Baumruker, P. Heining, R. Schmouder, G. Francis, S. Aradhye, and P. Burtin. 2010. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9: 883-897.
4. Cyster, J. G. 2005. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu. Rev. Immunol. 23: 127-159.
5. Kappos, L., J. Antel, G. Comi, X. Montalban, P. O'Connor, C. H. Polman, T. Haas, A. A. Korn, G. Karlsson, and E. W. Radue; FTY720 D2201 Study Group. 2006. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355: 1124-1140.
6. Jolly, P. S., M. Bektas, A. Olivera, C. Gonzalez-Espinosa, R. L. Proia, J. Rivera, S. Milstien, and S. Spiegel. 2004. Transactivation of sphingosine-1-phosphate receptors by FcepsilonRI triggering is required for normal mast cell degranulation and chemotaxis. J. Exp. Med. 199: 959-970.
7. Maeda, Y., H. Matsuyuki, K. Shimano, H. Kataoka, K. Sugahara, and K. Chiba. 2007. Migration of CD4 T cells and dendritic cells toward sphingosine 1- phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3. J. Immunol. 178: 3437-3446.
8. Roviezzo, F., F. Del Galdo, G. Abbate, M. Bucci, B. D'Agostino, E. Antunes, G. De Dominicis, L. Parente, F. Rossi, G. Cirino, and R. De Palma. 2004. Human eosinophil chemotaxis and selective in vivo recruitment by sphingosine 1- phosphate. Proc. Natl. Acad. Sci. USA 101: 11170-11175.
9. Kveberg, L., Y. Bryceson, M. Inngjerdingen, B. Rolstad, and A. A. Maghazachi. 2002. Sphingosine 1 phosphate induces the chemotaxis of human natural killer cells: role for heterotrimeric G proteins and phosphoinositide 3 kinases. Eur. J. Immunol. 32: 1856-1864.
10. Keul, P., S. Lucke, K. von Wnuck Lipinski, C. Bode, M. Gräler, G. Heusch, and B. Levkau. 2011. Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis. Circ. Res. 108: 314-323.
11. Ulrych, T., A. Böhm, A. Polzin, G. Daum, R. M. Nüsing, G. Geisslinger, T. Hohlfeld, K. Schrör, and B. H. Rauch. 2011. Release of sphingosine-1- phosphate from human platelets is dependent on thromboxane formation. J. Thromb. Haemost. 9: 790-798.
12. Walzer, T., L. Chiossone, J. Chaix, A. Calver, C. Carozzo, L. Garrigue-Antar, Y. Jacques, M. Baratin, E. Tomasello, and E. Vivier. 2007. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat. Immunol. 8: 1337-1344.
13. Jenne, C. N., A. Enders, R. Rivera, S. R. Watson, A. J. Bankovich, J. P. Pereira, Y. Xu, C. M. Roots, J. N. Beilke, A. Banerjee, et al. 2009. T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow. J. Exp. Med. 206: 2469-2481.
14. Rathinasamy, A., N. Czeloth, O. Pabst, R. Förster, and G. Bernhardt. 2010. The origin and maturity of dendritic cells determine the pattern of sphingosine 1- phosphate receptors expressed and required for efficient migration. J. Immunol. 185: 4072-4081.
15. Zhang, Z., Z.-Y. Zhang, U. Fauser, and H. J. Schluesener. 2008. FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves. Exp. Neurol. 210: 681-690.
16. Rausch, M., P. Hiestand, C. A. Foster, D. R. Baumann, C. Cannet, and M. Rudin. 2004. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging 20: 16-24.
17. Martini, S., S. Krämer, T. Loof, Y. Wang-Rosenke, U. Daig, K. Budde, H.-H. Neumayer, and H. Peters. 2007. S1P modulator FTY720 limits matrix expansion in acute anti-thy1 mesangioproliferative glomerulonephritis. Am. J. Physiol. Renal Physiol. 292: F1761-F1770.
18. Keul, P., M. Tölle, S. Lucke, K. von Wnuck Lipinski, G. Heusch, M. Schuchardt, M. van der Giet, and B. Levkau. 2007. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 27: 607-613.
19. Ogawa, R., M. Takahashi, S. Hirose, H. Morimoto, H. Ise, T. Murakami, T. Yasue, K. Kuriyama, M. Hongo, E. Kobayashi, and U. Ikeda. 2007. A novel sphingosine-1-phosphate receptor agonist KRP-203 attenuates rat autoimmune myocarditis. Biochem. Biophys. Res. Commun. 361: 621-628.
20. Singer, I. I., M. Tian, L. A. Wickham, J. Lin, S. S. Matheravidathu, M. J. Forrest, S. Mandala, and E. J. Quackenbush. 2005. Sphingosine-1- phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes. J. Immunol. 175: 7151-7161.
21. Gergely, P., B. Nuesslein-Hildesheim, D. Guerini, V. Brinkmann, M. Traebert, C. Bruns, S. Pan, N. S. Gray, K. Hinterding, N. G. Cooke, et al. 2012. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br. J. Pharmacol. 167: 1035-1047.
22. Pan, S., W. Gao, N. Gray, Y. Mi, and Y. Fan, and The Genomics Institute of the Novartis Research Foundation. 2004. Immunosuppressant compounds and compositions. World Intellectual Property Organization, Geneva, Switzerland.
23. Liu, Y., D. Papoutsakis, and E. Roddy, and Novartis Pharma AG. 2010 New polymorphic form of 1-(4-{ L-[ (E)-4-cyclohexyl-3-trifluoromethyl- benzyloxyimino]- ethyl)-2-ethyl-bezy L)-azetidine-3-carboxylic. World Intellectual Property Organization, Geneva, Switzerland.
24. Kupershmidt, I., Q. J. Su, A. Grewal, S. Sundaresh, I. Halperin, J. Flynn, M. Shekar, H. Wang, J. Park, W. Cui, et al. 2010. Ontology-based meta-analysis of global collections of high-throughput public data. PLoS One 5: e13066.
25. Gautier, E. L., T. Shay, J. Miller, M. Greter, C. Jakubzick, S. Ivanov, J. Helft, A. Chow, K. G. Elpek, S. Gordonov, et al Immunological Genome Consortium. 2012. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat. Immunol. 13: 1118-1128.
26. Iijima, N., L. M. Mattei, and A. Iwasaki. 2011. Recruited inflammatory monocytes stimulate antiviral Th1 immunity in infected tissue. Proc. Natl. Acad. Sci. USA 108: 284-289.
27. Shi, C., and E. G. Pamer. 2011. Monocyte recruitment during infection and inflammation. Nat. Rev. Immunol. 11: 762-774.
28. Shiow, L. R., D. B. Rosen, N. Brdicková, Y. Xu, J. An, L. L. Lanier, J. G. Cyster, and M. Matloubian. 2006. CD69 acts downstream of interferon-α/β to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440: 540-544.
29. De Maria, R., M. G. Cifone, R. Trotta, M. R. Rippo, C. Festuccia, A. Santoni, and R. Testi. 1994. Triggering of human monocyte activation through CD69, a member of the natural killer cell gene complex family of signal transducing receptors. J. Exp. Med. 180: 1999-2004.
30. Codarri, L., G. Gyülvészi, V. Tosevski, L. Hesske, A. Fontana, L. Magnenat, T. Suter, and B. Becher. 2011. RORgt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 12: 560-567.
31. King, I. L., T. L. Dickendesher, and B. M. Segal. 2009. Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 113: 3190-3197.
32. El-Behi, M., B. Ciric, H. Dai, Y. Yan, M. Cullimore, F. Safavi, G.-X. Zhang, B. N. Dittel, and A. Rostami. 2011. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat. Immunol. 12: 568-575.
33. Uemura, Y., H. Ohno, Y. Ohzeki, H. Takanashi, H. Murooka, K. Kubo, and I. Serizawa. 2008. The selective M-CSF receptor tyrosine kinase inhibitor Ki20227 suppresses experimental autoimmune encephalomyelitis. J. Neuroimmunol. 195: 73-80.
34. Mildner, A., H. Schmidt, M. Nitsche, D. Merkler, U.-K. Hanisch, M. Mack, M. Heikenwalder, W. Brück, J. Priller, and M. Prinz. 2007. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat. Neurosci. 10: 1544-1553.
35. Fife, B. T., G. B. Huffnagle, W. A. Kuziel, and W. J. Karpus. 2000. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J. Exp. Med. 192: 899-905.
36. Ishii, M., J. G. Egen, F. Klauschen, M. Meier-Schellersheim, Y. Saeki, J. Vacher, R. L. Proia, and R. N. Germain. 2009. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 458: 524-528.
37. Liesz, A., L. Sun, W. Zhou, S. Schwarting, E. Mracsko, M. Zorn, H. Bauer, C. Sommer, and R.Veltkamp. 2011. FTY720 reduces post-ischemic brain lymphocyte influx but does not improve outcome in permanent murine cerebral ischemia. PLoS One 6: e21312.
38. Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory Committee. Fingolimod (NDA 22-527) Background Package. June 10, 2010. Available at: http://www.fda.gov/downloads/advisorycommittees/ committeesmeetingmaterials/drudr/ peripheralandcentralnervoussystemdrugsadvisorycommittee/ucm214670.pdf. Accessed: March 5, 2012.
39. Duong, C. Q., S. M. Bared, A. Abu-Khader, C. Buechler, A. Schmitz, and G. Schmitz. 2004. Expression of the lysophospholipid receptor family and investigation of lysophospholipid-mediated responses in human macrophages. Biochim. Biophys. Acta 1682: 112-119.